Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease... Show more
a developer of particle-based vaccines and therapeutics for prevention and treatment of human disease
Industry PharmaceuticalsGeneric
A.I.dvisor indicates that over the last year, LQDA has been loosely correlated with UNCY. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LQDA jumps, then UNCY could also see price increases.
| Ticker / NAME | Correlation To LQDA | 1D Price Change % | ||
|---|---|---|---|---|
| LQDA | 100% | -3.10% | ||
| UNCY - LQDA | 34% Loosely correlated | -5.47% | ||
| GOSS - LQDA | 34% Loosely correlated | -4.94% | ||
| VIR - LQDA | 32% Poorly correlated | -2.70% | ||
| KROS - LQDA | 32% Poorly correlated | -1.47% | ||
| MNKD - LQDA | 32% Poorly correlated | -4.87% | ||
More | ||||
| Ticker / NAME | Correlation To LQDA | 1D Price Change % |
|---|---|---|
| LQDA | 100% | -3.10% |
| Pharmaceuticals category (157 stocks) | 14% Poorly correlated | +2.61% |
| Pharmaceuticals: Generic category (84 stocks) | 9% Poorly correlated | +3.15% |
LQDA broke above its upper Bollinger Band on July 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 49 similar instances where the stock broke above the upper band. In of the 49 cases the stock fell afterwards. This puts the odds of success at .
The 10-day RSI Indicator for LQDA moved out of overbought territory on July 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 52 similar instances where the indicator moved out of overbought territory. In of the 52 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 68 cases where LQDA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for LQDA turned negative on July 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LQDA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved above the 0 level on July 22, 2026. You may want to consider a long position or call options on LQDA as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LQDA advanced for three days, in of 326 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 253 cases where LQDA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LQDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (68.966) is normal, around the industry mean (47.256). LQDA has a moderately high P/E Ratio (494.765) as compared to the industry average of (103.786). LQDA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.832). LQDA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (26.316) is also within normal values, averaging (115.273).